HEALTHCARE INSTITUTE OF NEW JERSEY for HEALTHCARE INSTITUTE OF NEW JERSEY
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Promoting awareness of the biopharmaceutical and medical technology sectors. Opposing the imposition of price controls in the Medicare Part D program. Generally supporting intellectual property rights. Opposing various legislative and executive efforts to impose an international price index. Promoting awareness of increasing antimicrobial/antifungal resistance. Supporting the PASTEUR Act S. 1355 and H.R. 2940. Supporting the modernization of prescribing information to allow digital in lieu of printed information (H.R. 1503). Opposing CMS and CMMI Part D Payment Modernization Model amendments to Medicare's Six Protected Classes. Supporting Ensuring Patient Access to Critical Breakthrough Products Act/MCET. Opposing TRIPS waivers. Supporting the extension of the SBIR program. Supporting the Saving Access to Laboratory Services (SALSA) Act (H.R. 2377 and S. 1000). Supporting changes to the small molecule portions of the Inflation Reduction Act. Supporting the Verifying Accurate Leading-edge IVCT Development (VALID) Act (H.R. 2369). Opposing proposed FTC changes to non-compete clauses. Supporting the restoration of the orphan drug tax credit (Cameron's Law, H.R. 1350). Generally supporting changes to the 340B program. Generally supporting efforts to require pharmacy benefit managers (PBMs) to pass on rebates to patients. Generally promoting awareness of concerns regarding the Centers for Medicare & Medicaid Services (CMS) National Coverage Determination (NCD) and Coverage with Evidence Development (CED) policies that restrict patient access. Raising awareness within Congressional offices about Ethylene Oxide and EPA proposed regulations. Submitted comments to the EPA comments with respect to their proposed amendments to the National Emission Standards for Hazardous Air Pollutants (NESHAP) for the Commercial Sterilization Facilities source category with respect to Ethylene Oxide, and EPAs Proposed Interim Decision and Draft Risk Assessment Addendum for Ethylene Oxide pursuant to the Federal Insecticide, Fungicide, and Rodenticide Act (FIFRA). Submitted comments to the FDA's Center for Drug Evaluation and Researchs (CDER) Discussion Paper regarding the use of Artificial Intelligence in Drug Manufacturing. Opposing the SMART Act (S. 1246).
| Lobbyist | Covered position, as disclosed |
|---|---|
| STEVE ISSENMAN | Cong. Page (87-88), Congressional Aide (1990's) |
| DEAN J PARANICAS | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.